Kofteridis Diamantis P, Valachis Antonis, Velegraki Maria, Antoniou Maria, Christofaki Maria, Vrentzos George E, Andrianaki Angeliki M, Samonis George
Department of Internal Medicine, University Hospital of Heraklion, Crete, Greece.
Department of Oncology, Mälarsjukhuset Eskilstuna, Sweden.
J Infect Chemother. 2014 Jul;20(7):412-6. doi: 10.1016/j.jiac.2014.03.003. Epub 2014 Apr 22.
Pneumocystis jirovecii (former carinii) pneumonia, is a life-threatening opportunistic infection occurring in immunocompromised hosts. The aim of this study was to investigate the predisposing factors, clinical features and outcome of Pneumocystis pneumonia (PCP) in HIV-negative patients. The medical records of 62 adult patients with PCP, hospitalized at the University Hospital of Heraklion, Crete, Greece during a 10-year period (2004-2013) were retrospectively reviewed. All patients were immunosuppressed prior to the development of PCP. Thirty one patients (50%) suffered malignant hematological disease, 16 (26%) solid tumor and 15 (24%) had chronic inflammatory disease. Only 17 (27%) had received long-term systemic corticosteroids. All had symptoms of pneumonia upon admission, while 12 (19%) were suffering respiratory failure. Twenty one (34%) had received trimethoprim/sulfamethoxazole (TMP-SMX) prophylaxis before the PCP onset. Eight patients (13%) were admitted to the ICU. Mortality attributable to PCP reached 29%. Mortality attributable to PCP was higher in patients with solid tumors. TMP-SMX prophylaxis failed in a significant portion of the present cohort. Hence, PCP should be included in the differential diagnosis in immunocompromised patients with symptoms from the respiratory tract even if TMP-SMX has been given as prophylaxis.
耶氏肺孢子菌(原称卡氏肺孢子菌)肺炎是一种发生于免疫功能低下宿主的危及生命的机会性感染。本研究旨在调查HIV阴性患者肺孢子菌肺炎(PCP)的易感因素、临床特征及预后。对希腊克里特岛伊拉克利翁大学医院在10年期间(2004 - 2013年)住院的62例成年PCP患者的病历进行了回顾性分析。所有患者在发生PCP之前均处于免疫抑制状态。31例患者(50%)患有恶性血液病,16例(26%)患有实体瘤,15例(24%)患有慢性炎症性疾病。只有17例(27%)接受过长期全身性皮质类固醇治疗。所有患者入院时均有肺炎症状,其中12例(19%)出现呼吸衰竭。21例(34%)在PCP发病前接受过甲氧苄啶/磺胺甲恶唑(TMP - SMX)预防治疗。8例患者(13%)入住重症监护病房。PCP导致的死亡率达29%。实体瘤患者中PCP导致的死亡率更高。在本队列的很大一部分患者中,TMP - SMX预防治疗失败。因此,即使已给予TMP - SMX进行预防,对于有呼吸道症状的免疫功能低下患者,也应将PCP纳入鉴别诊断。